Beyfortus (nirsevimab) - Sanofi
Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System. (PubMed, J Pediatr Clin Pract) - Oct 25, 2026 - "Social and structural disparities in nirsevimab uptake improved in the second season, whereas disparities in RSVpreF uptake persisted. The uptake of RSV preventive strategies increased across 2 seasons, with a higher uptake of maternal RSVpreF vaccination than nirsevimab." 
Journal • Obstetrics • Preventive care • Respiratory Diseases • Respiratory Syncytial Virus Infections
http://www.ncbi.nlm.nih.gov/pubmed/42909243
 
Annaliese J Calzadilla; Anne-Marie Rick; Hui Liu; Jessica E Kerr
 
Oct 25, 2026
 
Prev Next